Focus: GSK is a London-based Big Pharma with 70,000 employees specializing in small molecules, vaccines, and biologics across vaccines, infectious disease, HIV/AIDS, oncology, and immunology. The company operates as a mature, publicly traded entity with a diversified but heavily concentrated product portfolio.
Profile data last refreshed 16h ago · AI intelligence enriched 2mo ago
Hot — 993 jobs added in 30d
Net +151 (993 new, 842 removed). Aggressive expansion phase.
GSK offers stability, scale, and commercial opportunity today, but the massive patent cliff and recent layoffs create medium-term career risk; best for those comfortable with restructuring cycles or seeking 3–5 year commercial roles before transition.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for GSK
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from GSK's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship triple-therapy inhaler representing 44% of company revenue; critical revenue driver through 2031 but faces steep decline post-LOE.
Dual-therapy respiratory asset with same LOE date as TRELEGY; second-largest revenue contributor in portfolio.
Dual-therapy LAMA/LABA inhaler facing patent expiry in late 2030; third-largest contributor to respiratory franchise.
Monotherapy LAMA with earliest LOE date in portfolio (December 2027); erosion risk is imminent and acute.
Legacy dual-therapy ICS/LABA with uncertain LOE; still generating significant revenue despite competitive pressure from newer inhalers.
Monotherapy ICS facing patent expiry in August 2026; first major LOE event in portfolio creates near-term headwind.
181 discontinued, 48 duplicate formulations not shown
+18 more products with revenue data
Stocks To Buy: Check Kush Bohra's Top Picks Of The Day | July 23, 2026 - NDTV Profit
Stocks To Buy: Check Kush Bohra's Top Picks Of The Day | July 23, 2026 NDTV Profit
GSK stock trades steadily as vaccines and specialty medicines support earnings - Ad-hoc-news.de
GSK stock trades steadily as vaccines and specialty medicines support earnings Ad-hoc-news.de
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval - MedCity News
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval MedCity News
GSK plc Stock (GSK) Closed Down by 3.17% on Jul 20: Facts Behind the Movement - TradingKey
GSK plc Stock (GSK) Closed Down by 3.17% on Jul 20: Facts Behind the Movement TradingKey
GSK stock trades steady as vaccine and specialty medicines growth underpins earnings - ad-hoc-news.de
GSK stock trades steady as vaccine and specialty medicines growth underpins earnings ad-hoc-news.de
GSK stock trades steady as upcoming results follow strong 2024 momentum - ad-hoc-news.de
GSK stock trades steady as upcoming results follow strong 2024 momentum ad-hoc-news.de
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent peer-reviewed publications with author affiliations at this company
Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study.
Effect of once-daily ICS/LAMA/LABA triple therapy versus ICS/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial.
+36 more products
Recent layoffs combined with $9.3B patent-cliff exposure create material career-continuity risk; employees should expect further restructuring announcements through 2027–2031 and plan accordingly.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo